OpenFDA + PubChem + ClinicalTrials.gov Integration

FDA Detox Medications & Clinical Research Encyclopedia

Official US Food & Drug Administration (FDA) monographs, PubChem chemical pharmacology profiles, and active ClinicalTrials.gov research studies for addiction recovery and 24/7 medical detox.

FDA-Approved MAT & Detox Medications

Partial Opioid Agonist / MAT

Buprenorphine / Naloxone

FDA Approved (2002)

Brand Names: Suboxone, Zubsolv, Sublocade

FDA Indication:

Maintenance treatment of opioid dependence as part of a complete treatment plan including counseling and psychosocial support.

Receptor Mechanism: Partial agonist at the mu-opioid receptor and antagonist at the kappa-opioid receptor.

🚨 FDA Boxed Warning: WARNING: RISK OF SERIOUS HARM OR DEATH WITH ACCIDENTAL INGESTION; ADDICTION, ABUSE, AND MISUSE.

Package NDCs:54868-5256-012496-1208-10093-5720-56

OpenFDA API SynchronizedFind MAT Centers Offering Suboxone

Full Opioid Agonist / OTP

Methadone Hydrochloride

FDA Approved (1947)

Brand Names: Methadose, Dolophine

FDA Indication:

Detoxification treatment of opioid addiction and maintenance treatment of opioid dependence in certified Opioid Treatment Programs (OTP).

Receptor Mechanism: Full agonist at the mu-opioid receptor and NMDA receptor antagonist.

🚨 FDA Boxed Warning: WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; QT PROLONGATION.

Package NDCs:0054-3556-630054-4571-25

OpenFDA API SynchronizedFind MAT Centers Offering Methadose

Opioid Receptor Antagonist

Naltrexone Extended-Release

FDA Approved (1984 (Oral) / 2006 (Vivitrol Injectable))

Brand Names: Vivitrol, ReVia

FDA Indication:

Prevention of relapse to opioid dependence following opioid detoxification, and treatment of alcohol dependence.

Receptor Mechanism: Competitive antagonist at mu-opioid receptors, blocking euphoric effects of opioids and alcohol.

🚨 FDA Boxed Warning: WARNING: RISK OF HEPATOTOXICITY AT EXCESSIVE DOSES; OPIOID OVERDOSE RISK IF OPIOID BLOCK IS OVERRIDDEN.

Package NDCs:65757-300-010056-0079-01

OpenFDA API SynchronizedFind MAT Centers Offering Vivitrol

Opioid Antagonist / Emergency Reversal

Naloxone Hydrochloride

FDA Approved (1971 (FDA Over-The-Counter Approved 2023))

Brand Names: Narcan, Kloxxado, Zimhi

FDA Indication:

Emergency treatment of known or suspected opioid overdose, manifested by respiratory and/or central nervous system depression.

Receptor Mechanism: Pure opioid antagonist that competes for and displaces opioids at mu-opioid receptor sites.

Package NDCs:69547-353-0270518-2450-0

OpenFDA API SynchronizedFind MAT Centers Offering Narcan

GABA Modulator / Glutamate Receptor Antagonist

Acamprosate Calcium

FDA Approved (2004)

Brand Names: Campral

FDA Indication:

Maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation.

Receptor Mechanism: Restores glutamate and GABA balance in the central nervous system altered by chronic alcohol exposure.

Package NDCs:0456-3200-01

OpenFDA API SynchronizedFind MAT Centers Offering Campral

Alcohol Dehydrogenase Inhibitor / Aversion Agent

Disulfiram

FDA Approved (1951)

Brand Names: Antabuse

FDA Indication:

Aid in the management of selected recovery patients who want to remain in a state of enforced sobriety from alcohol.

Receptor Mechanism: Inhibits aldehyde dehydrogenase (ALDH), leading to toxic accumulation of acetaldehyde upon alcohol consumption.

🚨 FDA Boxed Warning: WARNING: DISULFIRAM SHOULD NEVER BE ADMINISTERED TO AN INDIVIDUAL WHEN THEY ARE IN A STATE OF ALCOHOL INTOXICATION.

Package NDCs:0054-0065-25

OpenFDA API SynchronizedFind MAT Centers Offering Antabuse

MAT & Detox Centers Geo-Map

FDA-Approved Medication Assisted Treatment (MAT) Centers

Balanced 50-State coverage with municipal pin markers across all US regions

Filter Municipality:

Active US Clinical Research Trials (ClinicalTrials.gov APIv2)

Live interventional studies currently recruiting patients for addiction and detox research

NCT06678672RECRUITING (NA)

Contingency Management for Veteran Smokers Undergoing Major Elective Surgery

The goal of this study is to design and test the first mobile contingency management (CM) smoking cessation intervention for military Veterans undergoing major elective surgery. Smoking is the leading risk factor for postoperative complications and is associated with longer hospital stays, reoperations, and 30-day mortality. Smoking rates among patients undergoing major elective surgery are high, 22.3-43.0%. It is imperative to identify efficacious, strategically timed smoking cessation interventions for surgery patients. CM incentivizes smoking cessation through positive reinforcement (rewards) when bioverified abstinence is achieved. To ensure feasibility, CM must be tailored to the clinical context. CM for smoking cessation has never been delivered before and after major surgery, nor has mobile CM bioverification been trialed perioperatively. The investigators will develop and test a tailored mobile smoking cessation CM protocol for Veterans undergoing major elective surgery.

Sponsor: University of California, San Francisco

View Study on ClinicalTrials.gov

NCT07269119RECRUITING (NA)

Piloting a Deaf Accessible Pre-Treatment for AUD

This pilot study will evaluate the feasibility, acceptability, and preliminary efficacy of an adaptation of Motivational Enhancement Therapy (MET) titled "DeafMET", intended for Deaf adults with high-risk alcohol use. In this single intervention cycle, 10 Deaf participants will receive the DeafMET intervention delivered either in-person or via telehealth. Primary outcomes include change in participants' stage of change regarding alcohol use and measures of recruitment, retention, satisfaction, and adherence. Findings will inform further refinement of the intervention and planning for future research.

Sponsor: University of Massachusetts, Worcester

View Study on ClinicalTrials.gov

NCT05988931RECRUITING (NA)

Technology Interventions for Youth Alcohol Use

The purpose of this study is to evaluate the effects of two programs to prevent/reduce alcohol misuse among youth primary care patients. Depending on their study condition, youth will receive a brief web-based computer program or the web program + 8 weeks of supportive text messages. Parents/caregivers of youth are encouraged to use a freely available app to guide conversations with their child about drinking. This study will have significant impact by evaluating response to these scalable interventions which can be deployed widely in clinical care settings.

Sponsor: University of Michigan

View Study on ClinicalTrials.gov

NCT04810858RECRUITING (NA)

Modeling the Effects of Chronic Marijuana Use on Neuroinflammation and HIV-related Neuronal Injury

This study applies a hypothesis-driven approach to examine the effects of chronic marijuana use on HIV-associated inflammation and its subsequent impacts on central nervous system function, with the goal of identifying the mechanisms through which cannabinoids modulate neurological disorders and other comorbidities in persons with HIV.

Sponsor: Wake Forest University Health Sciences

View Study on ClinicalTrials.gov

50-State Geographic Directory